SCHEMBL188200

SCHEMBL188200

CN(C)CC(=O)N1CCNCC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 2/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA9 Q16790 1/20 0.43
CHKA P35790 1/20 0.42
CHRNB2 P17787 1/20 0.41
CHRNA3 P32297 1/20 0.41
CHRNA4 P43681 1/20 0.41
CHRNB3 Q05901 1/20 0.41
CHRNA6 Q15825 1/20 0.41
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.40
TPSAB1 Q15661 1/20 0.40
TPSD1 Q9BZJ3 1/20 0.40
TPSG1 Q9NRR2 1/20 0.40
GNAI3 P08754 4/20 0.38
GNAO1 P09471 4/20 0.38
GNAI1 P63096 4/20 0.38
DDB1 Q16531 1/20 0.38
CRBN Q96SW2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL3636826 0.98 CA2 (0.42) CA2CA12CA1CA9CHKA
SCHEMBL18476010 0.98 CA2 (0.42) CA2CA12CA1CA9CHKA
Hydrochloric Acid SCHEMBL30171799 0.98 CA2 (0.42) CA2CA12CA1CA9CHKA
SCHEMBL20458954 0.93 CA2 (0.46) CA2CA12CA1CA9CHKA
Trifluoroacetic Acid SCHEMBL27188793 0.88 PKM (0.43) CA2CA12CA1CA9CHKA
Trifluoroacetic Acid SCHEMBL22123169 0.88 PKM (0.43) CA2CA12CA1CA9CHKA
Tert-Butyl Formate SCHEMBL28785798 0.83 GAA (0.40) CA2CA12CA1CA9CHKA
SCHEMBL25170359 0.82 CA2 (0.39) CA2CA12CA1CA9CHKA
SCHEMBL11948185 0.80 ATM (0.44) KDM4EGAAITGB3ITGA2B
SCHEMBL4630504 0.80 ATM (0.50) KDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212131-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-07-06 US claimed
EP-4161921-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF Anima Biotech Inc. (US) 2023-04-12 EP claimed
WO-2021252555-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-12-16 WO claimed
CN-108101889-A Deuterated N- [5- (pyrimidine -2- amino) -2,4- di-substituted-phenyls]-trans -2,4- Pentadienamides 天津大学 2018-06-01 CN claimed
CN-108047207-A N- [5- (pyrimidine -2- amino) -2,4- di-substituted-phenyls] the deuterated objects of -2- fluoropropenes amides and application 天津大学 2018-05-18 CN claimed
WO-2026102212-A1 MACROCYCLIC MCL-1 INHIBITORS VANDERBILT UNIVERSITY (US) 2026-05-15 WO disclosed
EP-4161931-B1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2026-02-18 EP disclosed
US-20240376073-A1 QUATERNARY AMMONIUM CATION SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS HOFFMANN-LA ROCHE INC. (US) 2024-11-14 US disclosed
EP-4367102-A1 QUATERNARY AMMONIUM CATION SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS F. Hoffmann-La Roche AG (CH) 2024-05-15 EP disclosed
CN-117715892-A Quaternary ammonium cation substituted compounds for the treatment of bacterial infections 豪夫迈·罗氏有限公司 2024-03-15 CN disclosed
EP-3640248-B1 AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) 2023-08-23 EP disclosed
US-20230212131-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-07-06 US disclosed
CN-1678607-A Nitrogen-containing aromatic ring derivatives EISAI CO LTD (JP) 2005-10-05 CN disclosed
US-20050187236-A1 Nitrogen-containing aromatic derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-08-25 US disclosed
WO-2005075461-A1 IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION ASTRAZENECA AB (SE) 2005-08-18 WO disclosed
EP-1522540-A1 AZAARENE DERIVATIVES Eisai Co., Ltd. (JP) 2005-04-13 EP disclosed
US-6211242-B1 CARDIOVASCULAR DISORDERS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-04-03 US disclosed
EP-0757670-B1 BENZAMIDE DERIVATIVES AS VASOPRESSIN ANTAGONISTS FUJISAWA PHARMACEUTICAL CO (JP) 1999-01-13 EP disclosed
EP-0757670-A1 BENZAMIDE DERIVATIVES AS VASOPRESSIN ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-02-12 EP disclosed
WO-1995029152-A1 BENZAMIDE DERIVATIVES AS VASOPRESSIN ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212131-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF COL1A1, COL2A1, COL14A1 CA2 4469/4885CA12 4793/4885CA1 4669/4885
US-20240376073-A1 QUATERNARY AMMONIUM CATION SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS CFTR, HRH1, HRH4 CA2 1660/4885CA12 4138/4885CA1 4198/4885
US-20050187236-A1 Nitrogen-containing aromatic derivatives NR0B2, NR0B1, NR4A1 CA2 1309/4885CA12 836/4885CA1 830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.